Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for leprosy patients: experimental drug dovramilast under trial

NCT ID NCT07172659

Recruiting now Disease control Sponsor: Medicines Development for Global Health Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental drug called dovramilast in 45 adults with moderate to severe leprosy type 2 reaction, a painful skin condition. Participants receive either dovramilast (100 mg or 150 mg) or standard treatments like prednisolone or thalidomide. The goal is to see if dovramilast can reduce skin lesions by 75% in 12 weeks and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Dovramilast
What this could lead to
If successful, dovramilast could offer a new treatment option for leprosy type 2 reaction, potentially reducing reliance on current therapies like steroids or thalidomide.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 45 participants. The drug is unapproved anywhere, and its safety and effectiveness are not yet proven. It may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ERYTHEMA NODOSUM LEPROSUM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lepromatous leprosy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ERYTHEMA NODOSUM LEPROSUM

Contacts and locations

Locations

  • Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli

    NOT_YET_RECRUITING

    Abomey-Calavi, Benin

  • Chr de Divo

    NOT_YET_RECRUITING

    Divo, Côte d’Ivoire

  • Harborview Medical Center, University of Washington

    NOT_YET_RECRUITING

    Seattle, Washington, 98104, United States

  • Philippine General Hospital, University of the Philippines, Manila

    RECRUITING

    Manila, Philippines

  • Programme national lutte contre la lèpre

    NOT_YET_RECRUITING

    Tôlanaro, Madagascar

  • Universitas Gadjah Mada

    NOT_YET_RECRUITING

    Yogyakarta, Indonesia

More trials for these conditions

Other studies related to the condition(s) this trial covers.